|
|
|
|
| |
A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of Bacillus Calmette-Guerin (BCG) or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenace BCG therapy
A trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment, or other standard treatment, for bladder cancer that has come back
HYMN: Now Open to Recruitment in centres across the UK
This trial is funded by Cancer Research UK, coordinated by the University of Birmingham CRUK- Clinical Trials Unit and sponsored by University College London.
Chief Investigator: Professor John Kelly, University College Hospital, London
Trial Coordinator: Kathryn Matthews, Cancer Research UK Clinical Trials Unit, Institute for Cancer
Studies, University of Birmingham, Edgbaston, Birmingham, B15 2TT
For detailed information visit the following link:
HYMN Trial University of Birmingham site;
Studio randomizzato controllato Synergo vs. BCG
Comparazione di ipertermia locale (LHT) somministrata con Synergo combinata con instillazione
intravescicale di Mitomicina C (MMC) versus instillazione intravescicale
immunoterapica del bacillo di Calmette Guérin (BCG) per il trattamento
coadiuvante (profilattico) in pazienti a rischio medio-elevato di carcinoma
transizionale superficiale della vescica (STCCB).
Medical Enterprises ongoing clinical study started in 2002. It is a randomized,
multi-center study. Urology departments in Hospitals from Italy, France, The
Netherlands, Germany, Belgium and Israel are participating in the study.
Capo indagatore:
Prof J.A Witjes, Department of Urology, Radboud University Hospital,
Nijmegen, The Netherlands.
Popolazione dello Studio
Pazienti con
carcinoma transizionale superficiale della vescica a rischio medio-elevato (Ta,
T1, CIS) i quali vengono sottoposti a resezione transuretrale del loro tumore
come parte del trattamento medico ordinario.
|
Per ulteriori informazioni fare riferimento a: "Elenco degli ospedali"
|
|
| |
Home |
